Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Hi-gienic Ltd.

Ramot University Authority for Applied Research and Industrial

Hi-gienic Intra Vaginal Technologies Ltd.

Novagali Pharma Sa

Simon Benita

Taher Nassar

Theodor Stern

Ram Kluger

Raphael Mechoulam

Gregory Lambert

Mordechai Sokolovsky

Joseph Tam

Yoel Kloog

Dan Gibson

Tatyana Gershanik

Jackie Kleinstern

Taher Nasser

Shira Hirsh

Efrat Elbaz

Orit Amsalem

Aiman Abu Ammar

Menashe Levy

Liat Kochavi-Soudry

Jeffrey J Feigenbaum

Amit Badihi

Nour Karra

The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.

CB1R receptor blockers with acyclic backbones

Provided are Pt (IV) lipophilic derivatives for improved drug performance in cancer therapy, as well as nanocarriers including the same.

Pt (IV) derivatives and nanocarriers comprising them

Provided is a nanoparticle including a water-soluble protein, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by a metaphosphate.

Nanoencapsulation of hydrophilic active compounds

The present invention makes use of a unique methodology of double nano-encapsulation for protecting and controlling the release of active agents, either hydrophobic or hydrophilic, from stable nanoparticles of opposite characteristics. The protection of the active agent was achieved by loading the agent to be protected, into nanocarriers, which were subsequently encapsulated into sub-micron nanoparticles. The sub-micron nanoparticles formation has been successfully achieved by the use of novel nano spray techniques.

Nano delivery systems for siRNA

A formulation effective in reducing the pH in a menstruating vagina or in a tampon inserted therein to below pH 5.5, comprising (a) 3&#x2013;80% by weight of a solid organic acid polymer; (b) 92&#x2013;15% by weight of a solid organic acid; and (c) 5&#x2013;30% of a wetting agent. Also disclosed is a delivery system for releasing an active agent comprising: (a) a deposition comprising the active agent; and (b) a polymeric support on which the deposition is deposited. The delivery system is especially useful in a catamenial tampon for insertion in a human vagina which comprises (a) an inner core comprising an absorbent material; (b) an outer layer comprising a liquid permeable material; and (c) the delivery system.

pH reducing formulation and delivery system for a tampon

A transvaginal drug delivery system comprising: (a) a deposition comprising an effective amount of said drug and, optionally, a wetting agent; and (b) a polymeric support on which said deposition is deposited. Also disclosed is a catamenial tampon for insertion in a human vagina comprising: (a) an inner core comprising an absorbent material; (b) an outer layer comprising a liquid-permeable material; and (c) a delivery system according to the invention. A method of transvaginal drug delivery is also described.

System for transvaginal drug delivery

A formulation effective in reducing the pH in a menstruating vagina or in a tampon inserted therein to below pH 5.5, comprising (a) 3-80% by weight of a solid organic acid polymer; (b) 92-15% by weight of a solid organic acid, and (c) 5-30% of a wetting agent. Also disclosed is a delivery system for releasing an active agent comprising: (a) a deposition comprising the active agent; and (b) a polymeric support on which the deposition is deposited. The delivery system is especially useful in a catamenial tampon for insertion in a human vagina which comprises (a) an inner core comprising an absorbent material; (b) an outer layer comprising a liquid permeable material; and (c) the delivery system.

An oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs and cosmetic active agent; wherein the emulsion particles have a net positive charge (i.e. a positive zeta potential).

Oil-in-water emulsions of positively charged particles

Self-emulsifiable formulation producing an oil-in-water emulsion

A pharmaceutical composition being an oil in water type emulsion which comprises an effective amount of a lypophilic drug is provided. The composition comprises a synergistic combination consisting of about 3-50% of an oily carrier consisting of MCT oil optionally in combination with vegetable oil, about 0.05%-20% of a phospholipid, about 0.03-10% of a non-ionic surfactant, and about 0.05-5% of an ionic surfactant selected from the group consisting of bile-duct surface active agent, cholic acid and their derivatives.

Medicinal emulsions

The use of a compound of the formula: ##STR1## having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein A--B designates a 1(2) or a 6(1) double bond, R designates --CH.sub.3 or --CH.sub.2 OH, R.sup.1 designates a hydrogen atom or a lower acyl group, and R.sup.2 designates (A) a straight-chained or branched C.sub.6-12 alkyl radical; or (B) a group --O--R.sup.3, in which R.sup.3 is a straight-chained or branched C.sub.5-9 alkyl radical or a straight-chained or branched alkyl radical substituted at the terminal carbon atom by a phenyl group in the manufacture of a medicament for reducing or preventing glutamate neurotoxicity. Some of the above compounds are novel, and their preparation is described. Also described is a method of treating acute injuries to the central nervous system associated with excitatory amino acid neurotoxicity, a method of treating chronic degenerative disease associated with gradual selective neuronal loss and a method of treating poisonings affecting the central nervous system by administering a pharmaceutical composition containing the above compound.

Growing community of inventors

Tel Aviv, Israel

Simon Benita